NVO• Stock
Novo Nordisk (NVO)
$138.50
+1.85% (24H)
Indicative Static SnapshotExecution State:🟢 IN_BUY_ZONE (Optimal Accumulation)
Composite Score:88/100
🛡️ Strategic Moat & Fundamental Intelligence
Global GLP-1 weight-loss duopoly with Semaglutide/Wegovy franchise and oral formulation pipeline (Amycretin).
🔥 Upcoming Catalyst Milestone:
Medicare Part D Expanded GLP-1 Reimbursement Senate Floor Vote & Catalent Manufacturing Expansion.
🏛️ Regulatory & Political Context:
Foreign Affairs Committee Chairman Michael McCaul stock disclosure ($250k-$500k) with 92/100 Alignment.
Launch Interactive TradingView Chart & Position Sizer
Stream live order flow, VWAP overlays, options sweeps, and customized capital risk sizing for NVO.
🎯 Mark Minervini VCP Execution Ladder
View Execution Math Guide →Stop Loss (Exit)$132.96Invalidation Floor
Optimal Accumulation$136.28 - $138.50Institutional Pocket
Target 1 (Scale 50%)$149.57+2.5x ATR14 Expansion
Target 2 (Runner Exit)$158.44+4.5x ATR14 Extended
📊 5-Factor Fundamental DNA & Quality Scorecard
Piotroski Guide →Growth Score
89/ 100
Quality Score
94/ 100
Valuation Score
74/ 100
Momentum Score
86/ 100
Tail Risk Safety
85/ 100
Piotroski F-Score
8/ 9 (Pristine)